^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1-L

i
Entrez ID:
Related biomarkers:
1m
Tumor-related IGF2BP1-derived molecular subtypes to predict prognosis and immune microenvironment in head and neck squamous cell carcinoma. (PubMed, Front Immunol)
This study highlights the crucial link between RNA modification and TME diversity. Evaluating RNA modification in tumors improves our understanding of TME features and supports the development of effective immunotherapy strategies.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
|
PD-L1 expression • PD-L1-L
2ms
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. (PubMed, J Clin Oncol)
In this large, pooled nonrandomized retrospective analysis, we observed that NIVO + IPI provides longer OS than NIVO in patients with ICI treatment-naïve advanced melanoma and identifies clinical factors that appear to be associated with survival for each treatment, which may assist with treatment decision making.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
PD-L1 expression • BRAF mutation • BRAF wild-type • PD-L1-L
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
2ms
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). (PubMed, Urol Oncol)
BEMPEG plus NIVO did not meet the efficacy threshold for ORR in patients with previously untreated locally advanced or metastatic urothelial carcinoma and low PD-L1 expression.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • IL2 (Interleukin 2)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Opdivo (nivolumab) • bempegaldesleukin (NKTR-214)
2ms
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma. (PubMed, J Transl Med)
HNSCC patients with BM frequently have oropharyngeal primary sites and are HPV+. Common molecular alterations in BM samples, including targetable PIK3CA and ATM, were identified. MAP2K2 alterations were enriched and densities of immune cells were low, highlighting potential targets for further research and immunotherapy considerations.
Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • KMT2A (Lysine Methyltransferase 2A) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • TSC1 (TSC complex subunit 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • TSC1 mutation • PD-L1-L
2ms
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. (PubMed, ESMO Open)
In PD-L1low HER-2 negative GEAC, the benefit of first-line ICI is modest, yet significant. Further translational work is warranted to better select patients who could benefit from immunotherapy in this setting. Meanwhile, alternative therapeutic options such as zolbetuximab in Claudin18.2-positive disease must be taken into account.
Clinical • Journal • Checkpoint inhibition • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
|
HER-2 negative • PD-L1-L • HER-2 negative + CLDN18.2 positive
|
Vyloy (zolbetuximab-clzb)
2ms
Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • PD-L1-L
|
VENTANA PD-L1 (SP263) Assay
3ms
External reproducibility of PD-L1 IHC 22C3 pharmDx for esophageal cancer specimens at the CPS ≥ 1 cutoff (SITC 2024)
Background American Cancer Society estimates that 22,370 new cases of esophageal cancer were diagnosed in the United States in 2024.1 In March 2021, Pembrolizumab received FDA approval for use as monotherapy after one or more prior lines of systemic therapy for esophageal cancer patients with squamous cell histology that expresses PD-L1 (Combined Positive Score (CPS) ≥ 10) as determined by PD-L1 IHC 22C3 pharmDx...Conclusions This study demonstrates high reproducibility of PD-L1 IHC 22C3 pharmDx with respect to PD-L1 expression in esophageal cancer specimens at the CPS ≥ 1 cutoff. Ethics Approval The external reproducibility study was approved by WCG IRB, study numbers 1356915, 1357191, 1357539.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab)
3ms
Pepinemab a semaphorin 4D blockade antibody in combination with immune checkpoint therapies induces mature lymphoid aggregates correlating with clinical outcomes (SITC 2024)
The KEYNOTE-B84 study (NCT04815720) evaluated the safety and efficacy of pepinemab in combination with pembrolizumab as a first-line treatment for immunotherapy-naïve patients with R/M HNSCC. Biomarker studies conducted in patients with surgically resectable metastatic melanoma (NCT03769155) and HNSCC (NCT03690986) received neoadjuvant treatment with pepinemab/nivolumab/ipilimumab combinations compared to nivolumab or ipilimumab alone...Increased density and maturity of lymphoid aggregates correlated with disease control and longer progression-free survival (PFS). Conclusions Pepinemab, a Semaphorin 4D (SEMA4D) blocking antibody, in combination with ICB converts 'Cold' tumors to 'Hot' by inducing organized lymphoid aggregates.
Clinical • Clinical data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SEMA4D (Semaphorin 4D)
|
PD-L1 underexpression • PD-L1 negative • PD-L1-L • CXCR5 expression
|
Sema4 Signal®
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)
3ms
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
Efficacy for this combination at the RP2D was observed in tumors with low PD-L1 and was not dependent on FGFR3 gene alterations, suggesting broad potential benefit for patients with locally advanced/metastatic UC and FGFR mRNA overexpression. ClinicalTrials.gov Identifier: NCT03473756.
Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR overexpression • PD-L1-L
|
Tecentriq (atezolizumab) • rogaratinib (BAY 1163877)
3ms
Inhibition of Semaphorin 4D induces lymphoid aggregates, correlating with clinical outcomes when combined with immune checkpoint therapy (CRI-ENCI-AACR ICIC 2024)
Screening and on-treatment tumor biopsies were collected from several clinical trials: the KEYNOTE-B84 study (NCT04815720), that evaluated the safety and efficacy of pepinemab in combination with pembrolizumab as a first-line treatment for immunotherapy-naïve patients with R/M HNSCC, and biomarker neoadjuvant studies conducted in metastatic melanoma (NCT03769155) and HNSCC (NCT03690986) patients with surgically resectable disease treated with pepinemab/nivolumab/ipilimumab combinations compared to nivolumab or ipilimumab alone. When SEMA4D is blocked from binding to its receptors, suppression is reduced, leading to increased penetration and organization of antigen presenting cells (APC) and lymphoid cells in the tumor microenvironment. It is expected that this would facilitate interaction and communication among these cell populations, accounting for improved immune responses in otherwise "cold" tumors.
Clinical • Clinical data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SEMA4D (Semaphorin 4D)
|
PD-L1 underexpression • PD-L1-L • CXCR5 expression
|
Sema4 Signal®
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)
4ms
Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and its immune-microenvironment according to PD-L1 expression. (PubMed, Cancer Immunol Res)
In addition, a high ratio of CD8+ cells to M2 macrophages was found to predict favorable outcomes in patients with PD-L1-expressing lung cancer after immune checkpoint inhibitor therapy. This study demonstrates that TCs and ICs have distinct spatial features within the tumor microenvironment that are related to tumor PD-L1 expression and IC infiltration.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • PD-L1 overexpression • PD-L1-L
5ms
COMPARISON OF PD-L1 EXPRESSION BETWEEN PREOPERATIVE BIOPSY SPECIMENS AND SURGICAL SPECIMENS IN NON-SMALL CELL LUNG CANCER (CHEST 2024)
PD-L1 expression may differ between preoperative biopsy and surgery. CLINICAL IMPLICATIONS: When comparing the benefit of preoperative, postoperative or perioperative immunotherapy, the timing of PD-L1 expression assessment as a biomarker test for immunotherapy requires caution.
PD(L)-1 Biomarker • IO biomarker • Biopsy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
5ms
Clinical
|
PD-L1 expression • BRAF V600E • KRAS G12C • BRAF V600 • RET fusion • PD-L1 underexpression • ROS1 fusion • RET rearrangement • KRAS G12 • KRAS G12C + PD-L1 expression • PD-L1-L • NTRK fusion
5ms
Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial (ESMO 2024)
P2, P2a | "In comparison to data from international phase III trials, the majority of patients had a low PD-L1 CPS. No significant difference in clinical efficacy of FOLFOX/CAPOX & P followed by consolidation O & P in pts. with PD-L1 CPS ≥1 versus CPS <1 was observed."
P2 data
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency)
|
PD-L1 expression • HER-2 negative • HRD • TMB-L • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • TruSight Oncology 500 Assay
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • 5-fluorouracil • leucovorin calcium
5ms
First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS<5: Updated results of a phase II, prospective, single-arm study (ESMO 2024)
Here we presented the updated data as more pts were recruited. mGEA pts with PD-L1 CPS<5 and HER2(-) received tislelizumab and bevacizumab, in combination with standard CAPOX regimen up to 8 cycles, followed by tislelizumab, bevacizumab and capecitabine until disease progression. Tislelizumab plus bevacizumab and CAPOX demonstrated promising efficacy in PD-L1 <5, HER2(-), locally advanced or metastatic GEA pts, with a manageable safety profile. This trial is ongoing and the regimen deserves further exploration.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • GSTP1 (Glutathione S-transferase pi 1)
|
PD-L1 expression • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx
|
Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine
7ms
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression. (PubMed, Mol Clin Oncol)
In conclusion, first-/second-generation EGFR-TKIs and osimertinib were associated with a similar EGFR-TKI treatment duration in patients with EGFR-mutant NSCLC with negative or low PD-L1 expression. The findings suggested that both treatments are promising for this population.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR T790M • PD-L1-L
|
Tagrisso (osimertinib)
8ms
The efficacy of immune checkpoint inhibitors on low PD-L1 cervical cancer: A meta-analysis. (PubMed, Health Sci Rep)
In patients with CC and low PD-L1 expression, ICI monotherapy may not be considered as the optimal treatment strategy when compared to non-ICI treatment or ICI combination therapy. CRD42023395103.
Clinical • Retrospective data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
8ms
Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by preconditioning the tumor microenvironment. (PubMed, Cancer Sci)
As a result, even so-called cold tumors exhibited complete responses after αPD-L1-PIT. Thus, combination therapy of PEGylated IFNγ and PD-L1-targeted NIR-PIT has the potential to be an important future strategy for cancer immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
PD-L1 expression • PD-L1 overexpression • PD-L1-L
8ms
Predictive value of PD-L1 expression IHC on histology vs. cytology-specimen in non-small cell lung cancer (NSCLC) cohort in Leicester (BTOG 2024)
Similar to published reports, within the cohort of patients at Leicester 40.1% had PD-L1 testing on cytology samples. Histology samples had a better PFS and OS in intermediate and low PD-L1 cohorts, but Cytology samples had improved PFS in the high PD-L1 population. This study validates the use of PD-L1 IHC on cytology as a predictive marker for response to CPI in NSCLC.
PD(L)-1 Biomarker • IO biomarker • PD(L)-1 companion diagnostic • IO Companion diagnostic • Cytology
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx
8ms
Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses. (PubMed, BMC Cancer)
Patients with STK11-mutant NSCLC had low PD-L1 expression and ORR to ICIs, and their PFS and OS were worse than patients with STK11wt after comprehensive treatment. In the future, more reasonable systematic treatments should be explored for this subgroup of patients with STK11-mutant NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • STK11 (Serine/threonine kinase 11)
|
PD-L1 expression • STK11 mutation • PD-L1-L
|
5-fluorouracil • vinorelbine tartrate • Nutlin-3
8ms
Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy. (PubMed, J Med Chem)
Subsequently, we administered Ir-UA combined with anti-PD-L1 in mice, which effectively inhibited tumor growth and promoted CD4+ and CD8+ T cell infiltration. To our knowledge, Ir-UA is the first iridium-based complex to stimulate the expression of PD-L1 by explicitly regulating its transcription factors, which not only provides a promising platform for immune checkpoint blockade but, more importantly, provides an effective treatment strategy for patients with low PD-L1 expression.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ATF3 (Activating Transcription Factor 3)
|
PD-L1 expression • PD-L1-L
9ms
Immune checkpoints in autoimmune vasculitis. (PubMed, Best Pract Res Clin Rheumatol)
Uninhibited CD4+ T cells expand, release copious amounts of the cytokine Interleukin (IL)-9, and differentiate into long-lived effector memory cells. These data place GCA and cancer on opposite ends of the co-inhibition spectrum, with cancer patients developing immune paralysis due to excessive inhibitory checkpoints and GCA patients developing autoimmunity due to nonfunctional inhibitory checkpoints.
Review • Journal
|
PD-L1 (Programmed death ligand 1) • NOTCH1 (Notch 1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • CD96 (CD96 Molecule)
|
PD-L1-L
9ms
Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer. (PubMed, Sci Rep)
Patients with HER2-overexpressing OC exhibited distinct histological, IHC, and genomic profiles. HER2-targeting agents are potential options for BRCA-wildtype patients, particularly as later lines of treatment.
Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • BRCA (Breast cancer early onset)
|
PD-L1 expression • TP53 mutation • KRAS mutation • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • PD-L1 underexpression • ARID1A mutation • BRCA wild-type • TP53 expression • BRCA mutation • HER-2 amplification + PD-L1 expression • PD-L1-L
9ms
Role of CD38 in anti-tumor immunity of small cell lung cancer. (PubMed, Front Immunol)
A combination of cisplatin/etoposide, ICB, and CD38 blockade delayed tumor growth compared to cisplatin/etoposide. Our study provides a preliminary but important direction toward exploring CD38 as a potential biomarker of ICB response and CD38 blockade as a combination strategy for chemo-immunotherapy in SCLC.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • TMB-H • CD38 expression • CTLA4 expression • PD-L1-L • FOXP3 expression
|
cisplatin • etoposide IV
9ms
PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer. (PubMed, Transl Lung Cancer Res)
The patients were enrolled in clinical trials for immune checkpoint inhibitors (ICIs), including nivolumab, pembrolizumab, atezolizumab, durvalumab, tremelimumab, and camrelizumab. For the patients who were treated with immunotherapy alone (n=64), a similar PFS advantage was observed in the high PD-L1 group (2.8 vs. 8.0 months, P=0.002). This article presented the first data on TEP-derived PD-L1 mRNA in advanced NSCLC patients following immunotherapy and showed the potential advantage of using it as the surrogate biomarker for predicting the PFS and overall survival of patients following immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR wild-type • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • AiRuiKa (camrelizumab) • Imjudo (tremelimumab-actl)
9ms
Indi-Blade: Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (clinicaltrials.gov)
P2, N=50, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> Sep 2025
Enrollment closed • Trial primary completion date • Checkpoint inhibition
|
TMB (Tumor Mutational Burden)
|
PD-L1-L
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
10ms
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab) • WM-A1-3389
10ms
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer. (PubMed, J Extracell Vesicles)
Patients with high baseline levels of PD-L1+ lEVs in blood showed a significantly better response to immunotherapy and prolonged survival. This was particularly true in the subgroup of NSCLC patients with low or absent tPD-L1 expression, thus identifying PD-L1-positive lEVs in plasma as a novel predictive and prognostic marker for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SELP (Selectin P)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
10ms
Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients. (PubMed, Thorac Cancer)
PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • PD-L1 overexpression • KRAS G12C • ALK positive • PD-L1 underexpression • PD-L1 negative • KRAS G12 • EGFR positive • KRAS G12C + PD-L1 expression • PD-L1-L
10ms
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. (PubMed, EMBO Mol Med)
Using mice bearing genetically manipulated tumors, we confirmed that LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system. In conclusion, our results demonstrate the relevance of NAD+-related metabolic processes in antitumor immunity and suggest that co-targeting NAD+ metabolism and PD-L1 represents a promising therapeutic approach.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NAMPT (Nicotinamide Phosphoribosyltransferase)
|
PD-L1 expression • HIF1A expression • PD-L1-L
10ms
Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial (AACR 2024)
Cadonilimab plus chemo showed significant improvement in OS and PFS regardless of PD-L1 status and manageable safety profile, which could be a new standard first-line treatment option for advanced G/GEJ adenocarcinoma.Cutoff date: Aug 18, 2023
P3 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression • PD-L1-L
|
VENTANA PD-L1 (SP263) Assay
|
Kaitanni (cadonilimab)
10ms
Programmed Death-Ligand 1 (PD-L1) Expression in Penile Squamous Cell Carcinoma - A Comparative Assessment of the Reference Clone 22C3 with SP263 and E1L3N Clones along with a Correlation of Clinicopathologic and Survival Parameters (USCAP 2024)
1. Ours is the first study to demonstrate that SP263 and E3L1N can reliably be used to evaluate PD-L1 in PCs as there is good concordance with the reference clone 22C3. 2.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1 negative • CDKN2A negative • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
10ms
Molecular Alterations in Sarcomatoid Urothelial Carcinoma with Constitutive PDL-1 Overexpression (USCAP 2024)
Our results suggest that constitutive PD-L1 expression likely occurs due to upregulation of IL6-JAK-STAT3/ interferon alpha response pathways and provides a biologic rationale for evaluating response to immune checkpoint inhibitors and identifying potential exceptional responders in sUC.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
PD-L1 expression • PD-L1 overexpression • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
11ms
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice. (PubMed, Front Oncol)
In the real world, patients can clinically benefit from immunochemotherapy, regardless of the expression of PD-L1 and the histological type. Other clinicopathological factors such as performance status, extent, and location of secondary lesions have prognostic significance.
Journal • Combination therapy • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
|
Keytruda (pembrolizumab)
11ms
Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12. (PubMed, Mol Pharm)
Although immunohistochemistry (IHC) revealed a low PD-L1 expression in MDA-MB-213 and H2009 xenografts that corresponds well to the clinical situation, PET showed high tumor uptakes (6.6 and 7.3% injected activity per gram of tissue (iA/g), respectively) for Ga-68-TRAP-WL12. Thus, this tracer has the potential for routine clinical PD-L1 PET imaging because it detects even very low PD-L1 expression densities with high sensitivity and may open an avenue to replace PD-L1 IHC of biopsies as the standard means to select potential responders for ICT.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
11ms
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
In addition, patients with B7-H3 high and PD-L1 low expression showed the lowest anti-tumor immune infiltration, the highest collagen level, and the lowest therapeutic responses to multiple therapies, which mostly belong to armored-cold tumors. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression, which leads to a novel approach for the management of TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
|
PD-L1 expression • PD-L1 underexpression • CD276 expression • PD-L1-L
11ms
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial. (PubMed, Gynecol Oncol)
Dual immunotherapy with chemotherapy showed acceptable response rates and tolerable safety in HRR non-mutated PROC, warranting continued clinical investigation.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated) • EPCAM (Epithelial cell adhesion molecule) • FOXP3 (Forkhead Box P3) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
|
PD-L1 expression • PD-L1 overexpression • MUC16 mutation • EPCAM expression • PD-L1-L • FOXP3 expression
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
11ms
Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow. (PubMed, J Immunother Cancer)
ICI-based regimens are not associated with a survival benefit versus chemotherapy in subgroups of advanced/metastatic TNBC that express low PD-L1 levels.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1-L
|
Keytruda (pembrolizumab)
12ms
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy. (PubMed, Pharmacoeconomics)
The use of WGS-TMB is not cost effective compared to PD-L1 for immunotherapy treatment selection in non-squamous metastatic non-small cell lung cancer in the Netherlands. WGS-TMB could become cost effective provided there is a reduction in the cost of WGS testing or there is an increase in the predictive value of WGS-TMB for immunotherapy effectiveness. Alternatively, a combination strategy of PD-L1 testing with WGS-TMB would be cost effective if used to support the choice to withhold immunotherapy in patients with a low expected benefit of immunotherapy.
Journal • HEOR • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Cost-effectiveness • Cost effectiveness • Metastases
|
TMB (Tumor Mutational Burden)
|
TMB-H • PD-L1 underexpression • TMB-L • PD-L1-L
12ms
HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management. (PubMed, Clin Lung Cancer)
Lung cancer in PWH demonstrates unique features highlighting the need for a specialized screening program. Despite low PD-L1 expression, immunotherapy is well tolerated with reasonable disease control. Altered immune system in lung cancer pathogenesis in PWH should be further investigated.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PD-L1 expression • PD-L1-L
12ms
The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. (PubMed, Turk J Biol)
The activation of angiogenesis and metastasis-related pathways by anti-PD-L1 treatment in PD-L1 high tumors might be a tumor-promoting mechanism. The decrease of VEGFA, TGFβ1 and EGFR upon anti-PD-L1 treatment in PD-L1 low tumor cells provides a rationale for the use of those antibodies in PD-L1 low tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • PD-L1 overexpression • EGFR expression • PD-L1 underexpression • CDH1 expression • VEGFA expression • PD-L1-L
12ms
Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis. (PubMed, Clin Oncol (R Coll Radiol))
Among the evaluated perioperative immunochemotherapy regimens, toripalimab + chemotherapy indicated a significantly increased survival benefit for most resectable NSCLC patients. However, for high PD-L1 expression and non-squamous NSCLC patients, nivolumab + chemotherapy provided the most potent outcomes. Perioperative durvalumab + chemotherapy is a relatively safe treatment. The findings of this investigation are expected to assist clinicians in making informed decisions among promising treatment options.
Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative • PD-L1-L
|
Opdivo (nivolumab) • Imfinzi (durvalumab) • Loqtorzi (toripalimab-tpzi)